Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Small Molecules Studied
Download: Excel (XLSX), Comma-separated (CSV), Images (Zip file)
HMS LINCS ID | Name | Alternative Names | LINCS ID | Structure Image | PubChem CID |
---|---|---|---|---|---|
10249-1 | Epirubicin | Ellence | LSM-2078 | 41867 | |
10097-3 | Erlotinib | OSI-774 | LSM-1097 | 176870 | |
10250-1 | Etoposide | LSM-6348 | 36462 | ||
10235-2 | Everolimus | RAD001 | LSM-4258 | 53398658 | |
10251-1 | Fascaplysin | LSM-4272 | 73293 | ||
10110-3 | FR180204 | FR 180204; KIN001-230 | LSM-42790 | 11493598 | |
10508-1 | FTase Inhibitor I | B581 | 132887 | ||
10098-2 | Gefitinib | ZD1839; Iressa | LSM-1098 | 123631 | |
10108-2 | Geldanamycin | LSM-42789 | 644250 | ||
10252-1 | Gemcitabine | Gemzar | LSM-5333 | 60750 | |
10253-1 | Glycyl-H-1152 | LSM-4274 | |||
10509-1 | GM6001 | Ilomastat; Galardin; GM-6001 | 132519 | ||
10062-3 | GSK1070916 | KIN001-216 | LSM-1062 | 46885626 | |
10255-1 | GSK1838705A | LSM-4276 | 25182616 | ||
10013-3 | GSK461364 | GSK461364A | LSM-1013 | 15983966 | |
10257-1 | GSK923295 | LSM-4278 | 68651179 | ||
10029-2 | GW-5074 | LSM-1029 | 5034 | ||
10014-3 | GW843682X | GW843682 | LSM-1014 | 9826308 | |
10258-1 | Ibandronate | Boniva | LSM-4279 | 44828485 | |
10259-1 | ICRF-193 | LSM-4280 | 115150 | ||
10228-2 | IKK16 | LSM-2309 | 9549298 | ||
10023-3 | Imatinib | Gleevec; Glivec; CGP-57148B; STI-571 | LSM-1023 | 5291 | |
10260-1 | Ispinesib | SB-715992 | LSM-5732 | 6851740 | |
10261-1 | Ixabepilone | Azaepothilone B; Ixempra | LSM-43293 | 216344 | |
10208-2 | JNK-IN-5A | TCS JNK 5a; KIN001-188 | LSM-1209 | 766949 |